Fineline Cube

Follow:
14486 Articles
Hengrui Launches Henagliflozin Triple‑Combination Metformin for Type 2 Diabetes
CompanyDrug

Hengrui Launches Henagliflozin Triple‑Combination Metformin for Type 2 Diabetes

CSPC’s SYH2061 Injection Receives NMPA Clinical‑Trial Approval for IgA Nephropathy
CompanyDrug

CSPC’s SYH2061 Injection Receives NMPA Clinical‑Trial Approval for IgA Nephropathy

Boehringer Ingelheim’s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis
CompanyDrug

Boehringer Ingelheim’s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis

Fosun Pharma & Helsinn Partner to Produce Fosnetupitant for Akynzeo in China
CompanyDeals

Fosun Pharma & Helsinn Partner to Produce Fosnetupitant for Akynzeo in China

PADCEV Yields 60 % EFS Reduction in MIBC – Astellas‑Pfizer EV‑303 Study
CompanyDrug

PADCEV Yields 60 % EFS Reduction in MIBC – Astellas‑Pfizer EV‑303 Study

AbbVie’s SELECT‑SWITCH Study Confirms Upadacitinib Outperforms Adalimumab in RA
CompanyDrug

AbbVie’s SELECT‑SWITCH Study Confirms Upadacitinib Outperforms Adalimumab in RA

Harbour BioMed Reports Phase II Success of Porustobart in MSS mCRC
CompanyDrug

Harbour BioMed Reports Phase II Success of Porustobart in MSS mCRC

VBP 11th Finalizes 389 Participants, 3.7 Billion Doses Set for Centralized Procurement
Policy / Regulatory

VBP 11th Finalizes 389 Participants, 3.7 Billion Doses Set for Centralized Procurement

Roche Reports 7 % YoY Revenue Growth Through Q3 2025, Raises Full‑Year Guidance
Company

Roche Reports 7 % YoY Revenue Growth Through Q3 2025, Raises Full‑Year Guidance

Novo Nordisk Board Shake‑Up: Chairman Helge Lund and Six Members Step Down After Disagreement With Foundation
Company

Novo Nordisk Board Shake‑Up: Chairman Helge Lund and Six Members Step Down After Disagreement With Foundation

Innovent and Takeda Forge $11.4 B Partnership on IBI363, IBI343 & IBI3001 ADC Therapies
CompanyDeals

Innovent and Takeda Forge $11.4 B Partnership on IBI363, IBI343 & IBI3001 ADC Therapies

Galapagos Announces Exit from Cell‑Therapy Business After Strategic Review
Company

Galapagos Announces Exit from Cell‑Therapy Business After Strategic Review